Skip to content
Peptide Atlas
All peptides

CJC-1295

Tier 1 · Human trials
Also known as CJC1295 · DAC:GRF

The strongest evidence is Tier 1: the Teichman et al. 2006 Phase 1 randomised controlled trial in healthy adults and a related pulsatility RCT in healthy young men (src-1, src-2, src-5, src-15, src-29). However, multiple sources emphasize that human evidence rests essentially on this small Phase 1 work — no completed Phase 2 or Phase 3 efficacy trials exist, and a 2006 Phase II trial in HIV lipodystrophy patients was discontinued. Many use-case claims derive from Tier 2 animal/in-vitro work and Tier 3 vendor, consumer, and forum sources. CJC-1295 is not FDA-approved for any indication.

Half-life
~168 h
Routes
subcutaneous injection
Goals
growth hormone / IGF-1 elevation · muscle mass and recovery · fat loss / body composition · sleep quality · skin rejuvenation / anti-aging · performance enhancement
Cost / mg
Not recorded

How it works

According to Phase 1 trial reports and multiple reviews, CJC-1295 is a long-acting synthetic version of growth-hormone-releasing hormone (GHRH). Sources describe it as being built from the first 29 amino acids of natural GHRH with four amino-acid substitutions that make it resist breakdown by enzymes. The DAC (Drug Affinity Complex) version carries a chemical group that latches onto albumin, a blood protein, which sources say extends its active life from minutes to roughly a week. Reviews describe it binding the GHRH receptor on pituitary somatotroph cells to prompt the body's own growth hormone (GH) release, which in turn raises IGF-1. Sources emphasize that, unlike injecting GH directly, it amplifies the body's existing pulsatile GH pattern rather than replacing it.

Overview

Overview

A Phase 1 randomised trial in healthy adults reports that CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH) (src-1, src-2, src-5, src-15). Multiple sources describe it as a synthetically modified GHRH-(1–29)NH2 core carrying four amino-acid substitutions that make it more resistant to proteolytic cleavage (src-2, src-3, src-4, src-8, src-13); a peptide information site places these substitutions at positions 2, 8, 15 and 27 and describes them as designed to resist degradation by dipeptidyl peptidase-IV (DPP-IV) (src-4, src-8, src-13). A peptide guide states CJC-1295 was developed by ConjuChem, a Canadian biotechnology firm, in the early 2000s, and that it has never been approved by the FDA for any indication (src-6, src-8).

The DAC vs non-DAC distinction

Sources distinguish two forms. A peptide information site explains that the DAC (Drug Affinity Complex) version uses a maleimidopropionic acid group that forms a covalent bond with serum albumin at cysteine-34 after subcutaneous injection, with the majority becoming albumin-bound within 15–30 minutes (src-4, src-7). The same source states this extends the half-life from minutes to approximately 6–8 days, allowing once-weekly or biweekly dosing, whereas the Modified GRF(1-29) version lacking albumin binding has a half-life of approximately 30 minutes (src-4, src-7, src-8, src-11, src-13). A regulatory review similarly reports ~30 minutes without DAC and 6 days with DAC (src-3).

Key human findings (Teichman Phase 1 trial)

The Teichman trial reports that after a single subcutaneous injection, mean plasma GH concentrations rose dose-dependently by 2- to 10-fold for 6 days or more, and mean plasma IGF-I concentrations increased by 1.5- to 3-fold for 9–11 days (src-1, src-2, src-5, src-15). It estimated the half-life at 5.8–8.1 days (src-1, src-2, src-5, src-15). After multiple doses, mean IGF-I levels remained above baseline for up to 28 days with evidence of a cumulative effect (src-1, src-2, src-5, src-15). Subcutaneous administration produced sustained, dose-dependent GH and IGF-I increases in healthy adults aged 21–61 years over study durations of 28 and 49 days (src-1, src-2, src-5, src-15). A separate RCT in healthy 20- to 40-year-old men reports that CJC-1295 (half-life 8 days) increased GH secretion with preserved pulsatility — pulse frequency and magnitude were unaltered — while basal GH rose 7.5-fold (P<0.0001), mean GH rose 46% (P<0.01), and IGF-I rose 45% (P<0.001) (src-29); that study reported no significant differences between 60 and 90 μg/kg doses and suggested clinical utility in patients with intact pituitary GH secretory capability (src-29). A peptide information site reports that CJC-1295 amplifies the existing pulsatile GH pattern rather than replacing it (src-4, src-7).

Mechanism at the pituitary

Sources describe CJC-1295 binding the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary and stimulating GH production and release through a cyclic-AMP (cAMP)-dependent signaling cascade (src-4, src-6, src-8, src-13). A review characterizes it as a growth hormone secretagogue that activates IGF-1 signaling and satellite-cell repair (src-17). A GH-peptide guide states that GH output falls by roughly 14–15% per decade in healthy adults, that GH is secreted in four to nine discrete pulses per day driven by competing GHRH and somatostatin signals, and that the primary role of GHRH analogues like CJC-1295 is to increase GH pulse amplitude (src-8, src-10).

Animal and in-vitro evidence

In normal male Sprague Dawley rats, CJC-1295 showed a 4-fold increase in GH area-under-the-curve over 2 hours versus hGRF(1-29), was present in plasma beyond 72 hours, and appeared as an albumin-associated immunoreactive species after 15 minutes (src-25). In GHRH-knockout mice, once-daily 2 μg CJC-1295 over 5 weeks maintained normal body weight, length, bone length, and body composition, while less frequent dosing was less effective (src-26). An orthopaedic review reports that CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but that these findings are limited to animal studies and there is currently a lack of evidence supporting clinical use in orthopaedic applications (src-18).

Regulatory and use-case context

A peptide guide states no FDA-approved finished drug product containing CJC-1295 was identified, and no robust clinical trial evidence establishing combinations for anti-aging, body composition, sports recovery, or general wellness (src-6). CJC-1295 and CJC-1295 with DAC are prohibited by the World Anti-Doping Agency (WADA) under the S2 category (Peptide Hormones, Growth Factors and Mimetics) (src-3, src-11, src-13, src-20, src-30). Claimed uses reported across sources — improving GH and IGF-1, increasing muscle mass/strength, performance and recovery, energy, sleep, cognition, bone density, and weight management — largely derive from vendor pages, consumer guides, and forum analyses (src-12, src-14, src-16, src-21, src-45). A comparison article states CJC-1295 may improve muscle protein synthesis, enhance fat burning, and improve sleep quality (src-14), and consumer sources claim synergy with ipamorelin for lean mass and fat loss (src-16); these are not supported by controlled human efficacy data.

What the research shows

262 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 34 human trial findings, 2 human study findings, 8 animal findings and 11 expert opinion findings.

  • human trialSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels1

  • human trialAfter a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more2

  • human trialAfter a single injection of CJC-1295, mean plasma IGF-I concentrations increased by 1.5- to 3-fold for 9-11 d2

  • human trialAfter multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d2

  • human trialSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults2

  • human trialThere was evidence of a cumulative effect after multiple doses2

  • human trialAfter a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more3

  • human trialAfter a single injection of CJC-1295, there were dose-dependent increases in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d3

Show the remaining 47

  • human trialAfter multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d3

  • human trialAfter a single injection of CJC-1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more4

  • human trialAfter a single injection of CJC-1295, there were dose dependent increases in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d4

  • human trialAfter multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d4

  • human trialSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg4

  • human trialThere was evidence of a cumulative effect after multiple doses4

  • human trialAfter a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more5

  • human trialAfter a single injection of CJC-1295, there were increases in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d5

  • human trialAfter multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d5

  • human trialSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults5

  • human trialCJC-1295 is capable of stimulating GH production for more than six days in humans after a single administration8

  • human trialCJC-1295 stimulates GH and IGF-I secretion in several animal species and in normal human subjects11

  • human trialGH secretion was increased after CJC-1295 administration with preserved pulsatility11

  • human trialThe frequency and magnitude of GH secretory pulses were unaltered after CJC-1295 administration11

  • human trialBasal (trough) GH levels were markedly increased 7.5-fold (P < 0.0001) after CJC-1295 administration11

  • human trialOverall increase in mean GH levels of 46% (P < 0.01) after CJC-1295 administration11

  • human trialIGF-I levels increased by 45% (P < 0.001) after CJC-1295 administration11

  • human trialThe IGF-I increases did not correlate with any parameters of GH secretion11

  • human trialCJC-1295 DAC produces a dose-dependent increase in circulating insulin-like growth factor I (IGF-1) levels. In healthy adults, a single dose of 60 μg/kg resulted in IGF-1 elevations lasting up to 14 days12

  • human trialIn the Teichman et al. trial, IGF-1 levels continued to accumulate with repeated weekly dosing at 30 and 60 mcg/kg, suggesting progressive pharmacodynamic effect before plateau12

  • human trialA 2006 clinical trial showed CJC-1295 increased IGF-1 levels by up to 2- to 3-fold over baseline for about a month after a single injection series.21

  • human trialThe 2006 Teichman Phase 1 trial showed a single dose produced IGF-1 elevations of 1.5- to 3-fold above baseline lasting 9 to 11 days23

  • human trialA single subcutaneous dose of CJC-1295 with DAC (1–30 mcg/kg) produced dose-dependent mean GH elevations of 2- to 10-fold23

  • human trialPublished human RCT data (Teichman et al., J Clin Endocrinol Metab, 2006): a single SC injection produced 2–10× increases in plasma GH sustained for 6+ days26

  • human trialSingle SC injection produced 1.5–3× increases in IGF-1 lasting 9–11 days26

  • human trialIonescu & Frohman (2006) confirmed GH pulsatility is preserved during continuous CJC-1295 DAC stimulation26

  • human studyTeichman SL et al. (2006) confirmed sustained elevation of GH and IGF-1 across multiple days from a single injection, making once-weekly dosing viable20

  • human studyCJC-1295 can increase growth hormone and IGF-1 concentrations in healthy adults for days after subcutaneous administration25

  • animalCJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss13

  • animalCJC-1295 combined with ipamorelin findings are limited to animal studies13

  • animalGHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length16

  • animalMice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization16

  • animalFemur and tibia length remained normal in animals treated every 24 and 48 h16

  • animalRelative lean mass and subcutaneous fat mass were normal in all treated groups16

  • animalWhen the maleimido derivatives were individually administered sc to normal male Sprague Dawley rats, an acute secretion of GH was measured in plasma17

  • animalCJC-1295 showed a 4-fold increase in GH area under the curve over a 2-h period compared with hGRF(1-29)17

  • expert opinionTherapeutic peptides are a promising tool for treating type 2 diabetes and obesity, for skin rejuvenation, and as hormone analogs for specific diseases and conditions6

  • expert opinionCJC-1295 has limited clinical evidence compared to FDA-approved peptide therapeutics7

  • expert opinionCJC-1295 requires rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension7

  • expert opinionCJC-1295 has potential performance-enhancing effects15

  • expert opinionThere is no evidence that the general population is broadly deficient in endogenous peptides.18

  • expert opinionGray-market peptides are unapproved, loosely regulated compounds that lack scientific or medical consensus regarding their efficacy.18

  • expert opinionBiomarker movement alone is not sufficient; there must be evidence of durable clinical improvements.18

  • expert opinionTherapeutic peptides have demonstrated high potential to improve physical performance and body composition19

  • expert opinionNo completed Phase 2 or Phase 3 efficacy trials exist for CJC-129523

  • expert opinionNo FDA-approved combination product exists, and no robust clinical trial evidence was identified establishing such combinations for anti-aging, body composition, sports recovery, or general wellness25

  • expert opinionAdministering CJC 1295 once weekly helps to increase plasma GH concentrations (2-10 times)30

How it works

Based on 15 human trial findings, 4 animal findings, 7 in vitro findings, 46 expert opinion findings, 1 anecdotal finding and 3 theoretical findings.

  • human trialCJC-1295 is a long-acting analog of GH-releasing hormone2

  • human trialCJC-1295 is a long-acting analog of GH-releasing hormone (GHRH)3

  • human trialCJC-1295 is a long-acting GHRH analog with a synthetically modified core therapeutic moiety of GHRH-(1–29)NH2 modified by substitution of four amino acids to render the compound more resistant to proteolytic cleavage4

  • human trialCJC-1295 is a long-acting analog of GH-releasing hormone (GHRH)5

  • human trialCJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland8

  • human trialCJC-1295 incorporates a functional maleimido group at the C-terminus that allows it to covalently bind plasma proteins such as serum albumin8

  • human trialCJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland9

  • human trialCJC-1295 has a reactive maleimidopropionic acid group that covalently links the peptide to free thiols on the surface of plasma proteins9

Show the remaining 68

  • human trialSerum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog10

  • human trialCJC-1295 is a long-acting GHRH analog10

  • human trialTwo protein spots that displayed decreased intensities after CJC-1295 treatment were identified as an apolipoprotein A1 isoform and a transthyretin isoform10

  • human trialThree protein spots upregulated by CJC-1295 treatment included beta-hemoglobin, a C-terminal fragment of albumin, and a mix of an immunoglobulin fragment and another C-terminal albumin fragment10

  • human trialA linear relationship was found between the spot containing immunoglobulin and albumin fragments and IGF-1 levels10

  • human trialCJC-1295 is a synthetic GHRH analog that binds permanently to endogenous albumin after injection11

  • human trialUnlike exogenous GH administration, CJC-1295 amplifies the existing pulsatile pattern of GH secretion. Subjects receiving CJC-1295 DAC demonstrated elevated GH pulse amplitude while retaining the normal oscillatory secretion pattern12

  • animalCJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action16

  • animalCJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred16

  • animalAll three human serum albumin conjugates were bioactive in a GH secretion assay in cultured rat anterior pituitary cells17

  • animalCJC-1295 is a stable and active hGRF(1-29) analog with an extended plasma half-life17

  • in vitroCJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH)14

  • in vitroNineteen major in vitro metabolites of GHRH synthetic analogs including CJC-1295 were identified14

  • in vitroCJC-1295 is a 29 amino acid peptide with a C-terminal amide function15

  • in vitroCJC-1295 is a releasing factor for growth hormone15

  • in vitroThree maleimido derivates of human GH-releasing factor (hGRF)(1-29) were synthesized and bioconjugated to human serum albumin ex vivo17

  • in vitroAll three human serum albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV17

  • in vitroCJC-1295 is a tetrasubstituted form of hGRF(1-29) with an added N epsilon-3-maleimidopropionamide derivative of lysine at the C terminus17

  • expert opinionCJC-1295 is a modified GHRH (growth hormone releasing hormone)1

  • expert opinionCJC-1295 is a peptide therapeutic that modulates growth hormone7

  • expert opinionThe body naturally produces many peptides to serve essential functions, acting as signaling molecules, neurotransmitters, antioxidants, and transporters.18

  • expert opinionPeptide hormones include insulin, endorphins, and GLP-1.18

  • expert opinionScientists are able to engineer synthetic peptide-based therapies that mimic endogenous, body-produced molecules.18

  • expert opinionTherapeutic peptides people inject are rarely in their exact 'natural' form; most are heavily engineered analogs designed to artificially alter receptor binding, stability, and half-life.18

  • expert opinionA valid mechanism requires a defensible chain of steps from target engagement to a downstream biological effect; vague theoretical claims do not constitute a mechanism.18

  • expert opinionCJC-1295 and ipamorelin work synergistically to help increase lean mass while decreasing body fat19

  • expert opinionNatural GHRH has a half-life of about 7 minutes20

  • expert opinionDAC modification allows the peptide to bind to circulating albumin in blood20

  • expert opinionCJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to extend the half-life of natural GHRH, maintaining GH release over a longer period.21

  • expert opinionCJC-1295 binds GHRH receptors in the pituitary.21

  • expert opinionCJC-1295 produces sustained, gradual increases in GH and IGF-1.21

  • expert opinionIpamorelin is a growth hormone-releasing peptide (GHRP) that mimics ghrelin, a natural hunger hormone that also stimulates GH release.21

  • expert opinionIpamorelin binds GHS receptor (GHS-R1a) in the pituitary.21

  • expert opinionAfter peaking in adolescence, GH output falls by roughly 14–15% per decade in healthy adults22

  • expert opinionBy the time most people reach their fifties, their average daily GH secretion is a fraction of what it was at twenty-five22

  • expert opinionGrowth hormone is produced in the anterior pituitary gland and secreted in discrete pulses — not continuously22

  • expert opinionThose pulses are driven primarily by two competing hypothalamic signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it22

  • expert opinionOnce GH enters circulation, the liver converts much of it into insulin-like growth factor 1 (IGF-1), which is the downstream mediator responsible for most of GH's tissue-level effects — lean mass preservation, lipolysis, cellular repair, and collagen synthesis among them22

  • expert opinionWhen GH is released in timed pulses rather than maintained at steady-state levels, it produces meaningfully different metabolic effects — including better fat oxidation and a more favourable interaction with insulin sensitivity22

  • expert opinionGH peptides work upstream: they enhance the pituitary's own response to GHRH or ghrelin signals, preserving the pulse structure22

  • expert opinionGrowth hormone secretagogues are compounds that stimulate the secretion of GH and act on receptors — primarily the GHRH receptor or the ghrelin receptor (GHS-R1a) — to amplify the pituitary's natural signalling22

  • expert opinionWhen GH rises to a certain level, somatostatin steps in to suppress further release — a self-regulating mechanism that does not exist when you inject synthetic HGH directly22

  • expert opinionCJC-1295 is a GHRH analogue — a structurally modified version of native GHRH that binds the GHRH receptor on pituitary cells and stimulates GH synthesis and release22

  • expert opinionThe primary role of GHRH analogues like CJC-1295 is to increase the amplitude of GH pulses22

  • expert opinionCJC-1295 is a synthetic GHRH analog that stimulates pituitary growth hormone release23

  • expert opinionCJC-1295 incorporates four amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) and other plasma proteases23

  • expert opinionCJC-1295 binds the GHRH receptor (GHRHR) on the somatotroph cells of the anterior pituitary23

  • expert opinionConjuChem's strategy was to attach a drug affinity complex (DAC) — a reactive maleimido-propionic acid moiety — that covalently bonds to circulating albumin after injection, dramatically extending systemic residence time24

  • expert opinionCJC-1295 (both variants) acts as a selective agonist at the pituitary GHRH receptor (GHRH-R), a seven-transmembrane G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary24

  • expert opinionBinding activates adenylyl cyclase via Gs, elevating intracellular cyclic AMP and triggering a downstream cascade that opens voltage-gated calcium channels. The resulting calcium influx drives exocytosis of stored growth hormone24

  • expert opinionThe four amino acid substitutions in Mod GRF 1-29 — at positions two, eight, fifteen and twenty-seven of the native sequence — protect critical peptide bonds from dipeptidyl peptidase IV (DPP-IV) and other plasma proteases24

  • expert opinionGHRH drives discrete, rhythmic GH secretion pulses — typically four to nine per day in healthy adults24

  • expert opinionCJC-1295 no-DAC, administered in discrete injections, amplifies each natural GH pulse by saturating GHRH-R at the moment of hypothalamic signal arrival24

  • expert opinionCJC-1295 is a synthetic growth hormone-releasing hormone analog developed by ConjuChem as a longer-acting peptide intended to stimulate endogenous growth hormone secretion25

  • expert opinionGHRH binds receptors on pituitary somatotroph cells and stimulates growth hormone secretion; growth hormone then affects downstream mediators including insulin-like growth factor 1, or IGF-125

  • expert opinionThe DAC version incorporates a reactive group intended to form a covalent bond with endogenous albumin, extending circulating exposure compared with native GHRH or shorter GHRH analogs25

  • expert opinionCJC-1295 with DAC is a 30-amino acid synthetic analog of GHRH(1–29) incorporating ConjuChem Biotechnologies' proprietary compound Affinity Complex (DAC) technology26

  • expert opinionThe DAC component is a maleimido lysine derivative that covalently bonds to the free thiol of Cys34 on endogenous serum albumin after injection26

  • expert opinionCJC-1295 with DAC is mechanistically distinct from CJC-1295 without DAC: the No DAC version provides a 30-minute pulsatile GHRH signal; the DAC version provides sustained GHRH receptor stimulation over days26

  • expert opinionOnce bound to albumin, CJC-1295 is protected from peptidase degradation and its effective molecular size is dramatically increased reducing renal clearance26

  • expert opinionThe maleimide group spontaneously and covalently bonds to the free thiol group on Cys34 of endogenous serum albumin — the only free reactive thiol on circulating albumin26

  • expert opinionCJC-1295 is a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair28

  • expert opinionCJC 1295 is a growth hormone releasing hormone (GHRH) analogue30

  • expert opinionCJC 1295 has 4 amino acid substitutions in GHRH (1-29) to enhance activity and render it resistant to degradation by proteolytic enzymes30

  • anecdotalCJC-1295 is a synthetic growth hormone analogue29

  • theoreticalCJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of GHRH with four amino acid substitutions (positions 2, 8, 15, and 27) designed to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV)12

  • theoreticalCJC-1295 uses Drug Affinity Complex (DAC) technology, a reactive chemical group (maleimidopropionic acid) that forms a covalent bond with serum albumin following subcutaneous injection12

  • theoreticalCJC-1295 acts by binding to the GHRH receptor (GHRH-R) on somatotroph cells of the anterior pituitary gland, stimulating the production and release of growth hormone (GH) through a cyclic AMP (cAMP)-dependent signaling cascade12

Dosing

Based on 1 human trial finding, 2 animal findings and 9 expert opinion findings.

  • human trialNo significant differences were observed between responses to 60 or 90 microg/kg doses of CJC-129511

  • animalOnce-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice16

  • animalThe same dose is less effective when administered every 48 or 72 h16

  • expert opinionKnowledge gaps for CJC-1295 include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy7

  • expert opinionInformation regarding the indications, dosing, frequency, and duration of treatment for CJC-1295 remains unknown13

  • expert opinionCJC-1295 DAC typical dosing: once weekly 1 to 2 mg in a single subcutaneous injection20

  • expert opinionCJC-1295 DAC dosing: twice weekly 0.5 to 1 mg per injection, spaced 3 to 4 days apart20

  • expert opinionCJC-1295 without DAC typical dosing: once daily pre-bed20

Show the remaining 4

  • expert opinionCJC-1295 is often administered 1–2 times per week.21

  • expert opinionIpamorelin is typically injected daily or twice daily.21

  • expert opinionCJC 1295 dosage without DAC is 0.05 ml to 0.1 ml QHS, 5 days out of the week30

  • expert opinionCJC 1295 with DAC inject 600 mcg once weekly30

How the body handles it

Based on 14 human trial findings, 2 human study findings, 3 animal findings, 2 in vitro findings, 17 expert opinion findings and 4 theoretical findings.

  • human trialCJC-1295 DAC has a half-life of 6-8 days1

  • human trialCJC-1295 (DAC) has a cumulative effect observed after multiple doses1

  • human trialThe estimated half-life of CJC-1295 was 5.8-8.1 d2

  • human trialThe estimated half-life of CJC-1295 was 5.8-8.1 d3

  • human trialThere was evidence of a cumulative effect after multiple doses3

  • human trialThe estimated half-life of CJC-1295 was 5.8–8.1 d4

  • human trialNative GHRH, a 44-amino acid peptide, has a half-life of 7 min4

  • human trialThe estimated half-life of CJC-1295 was 5.8-8.1 d5

Show the remaining 34

  • human trialThere was evidence of a cumulative effect after multiple doses5

  • human trialCJC-1295-protein conjugates have a much greater half-life compared to the unconjugated peptide8

  • human trialConjugated CJC-1295 is difficult to detect in blood by mass spectrometry due to its low abundance, high molecular weight, and conjugation to a range of different protein substrates8

  • human trialOnce conjugated, CJC-1295 remains active in the bloodstream for significantly longer than non-conjugated peptide-based drugs that are rapidly excreted9

  • human trialCJC-1295 has a half-life of 8 days11

  • human trialThe terminal elimination half-life of CJC-1295 DAC is approximately 5.8-8.1 days, representing an approximately 200- to 400-fold extension compared to native GHRH (half-life 7-10 minutes) and a roughly 12- to 16-fold extension compared to the non-DAC version12

  • human studyDAC technology extends plasma half-life from ~30 minutes (for the unmodified peptide) to approximately 6–8 days26

  • human studyMeasured compound half-life of 6–8 days in human subjects26

  • animalGHRH analogs have a very short half-life16

  • animalCJC-1295 was found to be present in plasma beyond 72 h17

  • animalWestern blot analysis of rat plasma showed CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 min and remaining in circulation beyond 24 h17

  • in vitroGHRH synthetic analogs do not appear to have been found in anti-doping samples by WADA accredited laboratories, possibly due to their small concentration in urine and limited knowledge about their metabolism14

  • in vitroCJC-1295 undergoes in vitro metabolism that can be detected via liquid chromatography-tandem mass spectrometry14

  • expert opinionCJC-1295 has a longer half-life (30 minutes) compared to Sermorelin (11-12 minutes)1

  • expert opinionCJC-1295 with DAC has a half-life of roughly 6 to 8 days20

  • expert opinionCJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes20

  • expert opinionModified GRF 1-29 fragment has a half-life of around 30 minutes20

  • expert opinionCJC-1295 has a half-life of approximately 6–8 days with DAC modification.21

  • expert opinionIpamorelin has a half-life of approximately 2 hours.21

  • expert opinionThe DAC formulation covalently binds albumin to extend its half-life to approximately 6 to 8 days23

  • expert opinionCJC-1295 with DAC carries a maleimidopropionyl biotin linker that covalently binds to circulating albumin after subcutaneous injection23

  • expert opinionCJC-1295 without DAC has a plasma half-life of approximately 30 minutes23

  • expert opinionNative GHRH(1-29) degrades rapidly in plasma, with a half-life measured in minutes24

  • expert opinionResearchers reported mean half-lives of six to eight days and sustained IGF-1 elevation lasting up to fourteen days following a single subcutaneous dose24

  • expert opinionMod GRF 1-29 retains a half-life of approximately twenty-five to thirty minutes, pharmacologically resembling sermorelin more closely than the DAC form24

  • expert opinionThe DAC variant's albumin-binding mechanism produces a pharmacokinetic profile fundamentally different from its short-acting counterpart with sustained GHRH-R activation over six to eight days24

  • expert opinionThe DAC version is designed to bind albumin and has substantially different pharmacokinetics from shorter-acting modified GHRH(1-29)-type products25

  • expert opinionCJC 1295 without DAC has half-life of approximately 30 minutes30

  • expert opinionCJC 1295 with DAC has half-life of 6 days30

  • expert opinionIpamorelin half-life is 120 minutes30

  • theoreticalDAC technology extends the peptide's half-life from minutes to approximately 6-8 days, allowing for once-weekly or biweekly dosing12

  • theoreticalModified GRF(1-29) or Mod GRF 1-29 version lacks the albumin-binding functionality and has a substantially shorter half-life of approximately 30 minutes12

  • theoreticalThe maleimidopropionic acid (MPA) moiety on CJC-1295 DAC reacts with the free sulfhydryl group on cysteine-34 of circulating serum albumin, with the majority of the peptide becoming albumin-bound within 15-30 minutes of injection12

  • theoreticalWith weekly dosing, pharmacokinetic modeling predicts that CJC-1295 DAC reaches steady-state plasma concentrations by the second or third dose12

Safety and side effects

Based on 15 human trial findings, 1 animal finding, 23 expert opinion findings and 1 anecdotal finding.

  • human trialCJC-1295 (DAC) was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg1

  • human trialThe most frequently reported adverse events were injection site reactions, consisting of transient pain, swelling, and induration, sometimes accompanied by local urticaria1

  • human trialNo serious adverse reactions were reported in either Phase 1 study1

  • human trialCommon reported side effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and hives1

  • human trialA 2006 12-week Phase II clinical trial in 192 HIV patients with lipodystrophy reported 1 death from myocardial infarction; the attending physician believed this was unrelated to treatment1

  • human trialNo serious adverse reactions were reported2

  • human trialCJC-1295 was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg2

  • human trialNo serious adverse reactions were reported3

Show the remaining 32

  • human trialCJC-1295 was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg3

  • human trialNo serious adverse reactions were reported4

  • human trialNo serious adverse reactions were reported5

  • human trialCJC-1295 was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg5

  • human trialConjuChem advanced CJC-1295 DAC through Phase II clinical trials for adult growth hormone deficiency. Clinical development was discontinued following the death of a participant during a trial, reportedly due to a cardiovascular event12

  • human trialPreserved pulsatile GH release and no increase in prolactin, cortisol, or ACTH observed in human RCT26

  • human trialA 12-week, Phase II clinical trial for CJC-1295 DAC in lipodystrophy in 192 HIV patients reported 1 death from a myocardial infarction30

  • animalThe assay effectiveness for controlling illicit use of CJC-1295 was confirmed in equine blood samples after administration in thoroughbred race horses9

  • expert opinionFurther studies are needed before most new peptides can be used safely in humans6

  • expert opinionCJC-1295 is an investigational peptide that lacks long-term safety data and systematic validation7

  • expert opinionCurrent lack of evidence to support the clinical use of CJC-1295 in orthopaedic applications13

  • expert opinionCJC-1295 administration is prohibited by the World Anti-Doping Agency (WADA)14

  • expert opinionCJC-1295 is not FDA-approved20

  • expert opinionLong-term safety data in healthy adults for CJC-1295 remain limited; most research focuses on short-term GH/IGF-1 elevations.21

  • expert opinionCJC-1295 common side effects include mild injection-site reactions (redness, itching), water retention or mild bloating, and tingling or numbness in extremities (rare).21

  • expert opinionBoth CJC-1295 and Ipamorelin boost GH more safely than traditional HGH injections.21

  • expert opinionThe safety and side effect profile of GH secretagogues tends to be more favourable than that of exogenous HGH, particularly regarding IGF-1 overshoot and glucose dysregulation22

  • expert opinionCJC-1295 is classified as an FDA 503A Category 2 prohibited substance as of April 202623

  • expert opinionCJC-1295 is not FDA-approved for any indication23

  • expert opinionCJC-1295 is classified as a prohibited substance under the WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) category as of 202623

  • expert opinionFDA's December 4, 2024 Pharmacy Compounding Advisory Committee voted 0 yes, 13 no, and 0 abstentions for adding CJC-1295 free base to the 503A bulks list25

  • expert opinionCompounded drugs containing CJC-1295 may pose immunogenicity and peptide-impurity risks25

  • expert opinionFDA identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction25

  • expert opinionUnapproved peptides like CJC-1295 operate largely outside of regulatory oversight27

  • expert opinionMany unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce27

  • expert opinionCJC 1295 and CJC 1295 with DAC are banned by WADA (World Anti-Doping Agency)30

  • expert opinionCJC-1295 is reported safe in recommended dosages30

  • expert opinionMost common side effects include flushing, injection site erythema, rash, edema, joint and muscle pain, and fatigue30

  • expert opinionGH may be mitogenic; if patient prone to cancer or has cancer, use with caution30

  • expert opinionGH may mask symptoms of hypothyroidism; make sure to test thyroid hormone levels30

  • expert opinionSafety in pediatrics and in pregnancy has not been established30

  • anecdotalConcerns were described relating to female consequences of use given gender variations in growth hormone pulses affecting estimation of dosage, cycling, and long-term consequences29

What people use it for

Based on 2 human trial findings, 1 animal finding, 20 expert opinion findings and 7 anecdotal findings.

  • human trialSubcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults3

  • human trialCJC-1295 may have clinical utility in patients with intact pituitary GH secretory capability11

  • animalCJC-1295 enhances growth in rats11

  • expert opinionCJC-1295 improves GH and IGF-11

  • expert opinionCJC-1295 restores circadian growth hormone1

  • expert opinionCJC-1295 increases muscle mass/strength1

  • expert opinionCJC-1295 improves performance and recovery1

  • expert opinionCJC-1295 provides better energy, sleep, cognition, and bone density1

Show the remaining 22

  • expert opinionCJC-1295 provides weight management support1

  • expert opinionTherapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes6

  • expert opinionNovel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement6

  • expert opinionCJC-1295 is considered a Prohibited Substance under Section S2 of the WADA Prohibited List15

  • expert opinionGray-market peptides are widely labeled for 'research use only' as a semantic, legal strategy to avoid making explicit therapeutic claims.18

  • expert opinionTherapeutic peptides have demonstrated potential for weight loss, immune modulation, and cognitive enhancement19

  • expert opinionCJC-1295 can improve muscle protein synthesis.21

  • expert opinionCJC-1295 can enhance fat burning.21

  • expert opinionCJC-1295 can improve sleep quality.21

  • expert opinionCJC-1295 itself has never been approved by FDA for any indication25

  • expert opinionNo FDA-approved finished drug product containing CJC-1295 was identified25

  • expert opinionCJC-1295 is an unapproved peptide marketed direct to patients27

  • expert opinionCJC-1295 is used in sports medicine for accelerated injury recovery and performance enhancement27

  • expert opinionStimulates pituitary endogenous GH (growth hormone)30

  • expert opinionIncreases endogenous IGF-1 (insulin-like growth factor-1)30

  • anecdotalCJC-1295 is readily available and is being used within the bodybuilding community15

  • anecdotalCJC-1295 and ipamorelin can help facilitate muscle growth and fat loss19

  • anecdotalForum users reported use of CJC-1295 for weight loss29

  • anecdotalForum users reported use of CJC-1295 for muscle enhancement29

  • anecdotalForum users reported use of CJC-1295 for youthful skin29

  • anecdotalForum users reported use of CJC-1295 for improved sleep29

  • anecdotalForum users reported use of CJC-1295 for injury healing29

Other findings

Based on 2 human trial findings, 1 animal finding and 4 expert opinion findings.

  • human trialConjugation of CJC-1295 to plasma proteins prevents its detection by top-down mass-spectrometry-based peptide screening protocols9

  • human trialAn immuno-polymerase chain reaction (I-PCR) assay was developed capable of detecting the CJC-1295-protein conjugate at concentrations down to 0.8 pg/mL9

  • animalA screening threshold for CJC-1295 in equine plasma of 50 pg/mL was established to account for endogenous equine GHRH detection9

  • expert opinionPeptides are short chains of amino acids, generally smaller than proteins, consisting of relatively short strings of amino acids that can form straight lines or more complex ring structures.18

  • expert opinionCJC-1295 originated at ConjuChem Inc, a Canadian biotechnology firm, in the early 2000s as part of a programme designed to extend the pharmacological lifespan of endogenous growth hormone-releasing hormone (GHRH)24

  • expert opinionThe compound never advanced beyond Phase II and was never approved in any jurisdiction24

  • expert opinionCJC-1295 with DAC is available in a 2mg configuration with batch-specific COAs26

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Human evidence rests essentially on one small 2006 Phase 1 trial; no completed efficacy trials.

The core human findings (2-10x GH, 1.5-3x IGF-I, 5.8-8.1 d half-life) all trace to the Teichman et al. 2006 Phase 1 RCT and a related pulsatility study in healthy young men. Multiple sources note no completed Phase 2 or Phase 3 efficacy trials exist, long-term safety data are limited, and animal/orthopaedic findings do not support clinical use.

Contested

Reported half-life of the non-DAC version varies and the 6-day vs 6-8-day DAC figure differs slightly across sources.

Non-DAC (Modified GRF 1-29) half-life is cited as ~30 minutes by most sources but as 'twenty-five to thirty minutes' by one; native GHRH half-life is given as 7 minutes in some sources and 7-10 minutes in others. DAC half-life is stated as 6 days in one regulatory document but 6-8 days (and 5.8-8.1 d, and 8 d) elsewhere.

Contested

The Phase II trial death was attributed differently across documents.

A 2006 12-week Phase II trial in 192 HIV patients with lipodystrophy reported 1 death from myocardial infarction. One regulatory document notes the attending physician believed it was unrelated to treatment, while a peptide site frames the trial discontinuation as following the death reportedly due to a cardiovascular event.

Limited evidence

Many use-case claims come from vendor, forum, and low-tier sources, not clinical trials.

Claims of muscle growth, fat loss, improved sleep, skin rejuvenation, cognition, and injury recovery derive from tier-3 vendor pages, consumer guides, and analyzed forum posts (anecdotal/expert_opinion), not controlled human efficacy data. FDA identified serious adverse events and voted 13-0 against adding CJC-1295 to the 503A bulks list.

Single source

Amino-acid count is reported inconsistently (29 vs 30).

Some sources describe CJC-1295 as based on the 29-amino-acid GHRH(1-29) core, while others (including anti-doping studies and a vendor guide) describe it as a 30-amino-acid peptide, reflecting whether the DAC/lysine linker moiety is counted.

Using it with other compounds

Check a stack
  • IpamorelinComplementary

    May be complementary

    Ipamorelin works through a different receptor (the ghrelin/GHS-R1a receptor) than CJC-1295's GHRH-R. GHRH analogs increase the size of each GH pulse while ghrelin-mimetics increase pulse frequency and suppress somatostatin — so the two amplify each other's GH release. This GHRH + GHRP pairing is the classic synergistic GH stack.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly establish complementary action on the GH_axis and IGF1_signaling. CJC-1295 targets GHRH-R and amplifies endogenous pulsatile GH secretion via cAMP-PKA pathways, increasing GH pulse amplitude. Ipamorelin targets GHSR-1a (ghrelin receptor) and triggers pulsatile GH release via Gαq/11-PLC and cAMP-PKA pathways. The proposed explanation that GHRH analogs increase pulse size while ghrelin-mimetics increase pulse frequency is mechanistically consistent with their distinct receptor targets and signaling cascades. Both converge on GH secretion and downstream IGF-1 signaling but through different physiological mechanisms (GHRH stimulation vs. ghrelin mimicry), making them complementary rather than redundant. The shared dimensions (GH_axis, IGF1_signaling) are explicitly supported by both peptides' documented effects and approved tags.

    Timing Commonly co-administered in the same injection, typically on an empty stomach at night.

    Shares GH axis · IGF1 signaling

  • TesamorelinSame mechanism

    Worth caution

    Tesamorelin is also a stabilized GHRH analog acting on the same GHRH-R/cAMP pathway to raise GH and IGF-1. Combining it with CJC-1295 stacks two drugs doing the identical job, which is redundant and could over-drive IGF-1 without adding a distinct benefit. Choose one GHRH agent for a given goal.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they target the same GHRH receptor (GHRH-R/GHRHR) on anterior-pituitary somatotrophs and activate the identical cAMP-dependent signaling cascade (Gs-alpha/adenylate cyclase/cAMP/PKA pathway). Both produce dose-dependent increases in GH secretion and IGF-1 levels through the same endocrine axis. The shared mechanism tags (GH_axis, IGF1_signaling, cAMP_PKA) are explicitly supported by both descriptions. The proposed relationship correctly identifies that both are GHRH analogs operating through the same receptor and pathway, making them mechanistically redundant rather than complementary. The explanation's logic about stacking two agents with identical mechanisms is justified by the provided mechanism material.

    Timing Avoid running two GHRH analogs at once; select one.

    Shares GH axis · IGF1 signaling · cAMP PKA

  • SermorelinSame mechanism

    Worth caution

    Both are GHRH analogs that hit the exact same receptor (GHRH-R) on pituitary somatotrophs to trigger the cAMP-driven GH pulse. Stacking them is redundant rather than additive — you'd just be doubling up on one mechanism. CJC-1295 is longer-acting than sermorelin, so most people choose one or the other rather than combining.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish they are GHRH analogs targeting the same GHRH receptor on anterior pituitary somatotrophs. Both activate the cAMP/PKA pathway (Gs/adenylyl cyclase/cAMP) to stimulate GH secretion and downstream IGF-1 signaling. The shared dimensions (GH_axis, protein_synthesis, IGF1_signaling, cAMP_PKA) are explicitly documented in both mechanisms. The key mechanistic difference is pharmacokinetics (CJC-1295's albumin-binding confers longer half-life via DAC modification), not the fundamental signaling pathway or receptor target. The explanation that stacking would be redundant rather than additive is mechanistically sound given they engage identical downstream cascades through the same receptor. This qualifies as 'same_mechanism' with different duration profiles.

    Timing If transitioning, pick one GHRH agent rather than running both simultaneously.

    Shares GH axis · protein synthesis · IGF1 signaling · cAMP PKA

  • HexarelinComplementary

    Worth caution

    Hexarelin is a ghrelin-receptor (GHS-R1a) agonist, a different upstream mechanism from CJC-1295's GHRH receptor. The two converge on greater GH secretion, so combining amplitude (GHRH) with a secretagogue can be additive. Note hexarelin also stimulates ACTH/cortisol and prolactin and can desensitize its receptor over time, so it's less selective than ipamorelin.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly target the GH_axis and IGF1_signaling dimensions through distinct upstream pathways: CJC-1295 acts via GHRH-R (cAMP-dependent cascade), while Hexarelin acts via GHS-R1a (PLC/IP3/PKC cascade). The mechanisms explicitly show both increase plasma GH and IGF-1 levels through different receptor signaling routes, which justifies the 'complementary' relationship claim of convergent but mechanistically distinct GH stimulation. The explanation accurately reflects the provided mechanism material—different receptors, shared downstream GH/IGF-1 axis effects, and potential additive amplification of GH secretion.

    Timing Dose on an empty stomach; watch for cortisol/prolactin effects with repeated hexarelin use.

    Shares GH axis · IGF1 signaling

  • MK-677Complementary

    Worth caution

    MK-677 is an oral ghrelin-receptor agonist that raises GH/IGF-1 via a different receptor than CJC-1295. The mechanisms are complementary (pulse amplitude from GHRH vs. secretagogue-driven pulses), but because MK-677 produces sustained IGF-1 elevation, combining the two can push IGF-1 high — monitor levels and watch for water retention/appetite effects.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly establish complementary action on the GH axis through distinct receptors: CJC-1295 targets GHRH-R (direct GHRH pathway via cAMP-PKA cascade), while MK-677 targets GHS-R1a (ghrelin-mimetic pathway via Gq/11-PLC-IP3-calcium cascade). Both peptides share three approved tags (GH_axis, protein_synthesis, IGF1_signaling) and both increase pulsatile GH secretion and IGF-1 elevation, but through different mechanisms. The explanation correctly identifies the complementary nature: CJC-1295 amplifies endogenous pulsatile GH with preserved pulse pattern via GHRH-R, while MK-677 drives GH-vesicle exocytosis and modulates hypothalamic GHRH/somatostatin via GHS-R1a. The proposed shared dimensions are explicitly supported by the approved tags and mechanism descriptions for both peptides. The caveat about combined IGF-1 elevation and monitoring is a reasonable inference from the stated effects (2-10 fold GH increase for CJC-1295, sustained IGF-1 elevation for MK-677) but does not contradict the complementary relationship claim.

    Timing MK-677 is long-acting/daily; monitor IGF-1 if combined with a GHRH analog.

    Shares GH axis · protein synthesis · IGF1 signaling

  • KlothoStack with caution

    Worth caution

    CJC-1295 raises GH and IGF-1 by 1.5–3 fold, whereas Klotho's anti-aging action partly depends on restraining IGF-1/insulin signaling. Because the two push IGF-1 in opposite directions, combining them for longevity purposes may blunt Klotho's mechanism; the tension is theoretical but real and worth flagging.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims CJC-1295 and Klotho push IGF-1 signaling in 'opposite directions,' but the mechanism descriptions do not establish this opposition. Klotho's description lists 'IGF-1/insulin receptor signaling axis' as a target and 'IGF-1/insulin signaling' as a pathway, with effects including 'Improved insulin sensitivity/secretion' and 'Anti-senescence / longevity-associated effects.' This does not indicate Klotho restrains IGF-1 signaling; rather, it modulates it as part of its multi-target mechanism. CJC-1295 clearly increases IGF-1 (1.5–3 fold). The mechanisms do not establish that Klotho's longevity action 'depends on restraining' IGF-1 signaling, nor do they demonstrate a mechanistic conflict. The explanation relies on external reasoning about IGF-1 and aging that is not supported by the provided mechanism material. Both peptides engage IGF-1 signaling, but the descriptions do not justify the claimed directional opposition or the caution relationship.

    Shares IGF1 signaling

  • Follistatin-344Complementary

    Worth caution

    Follistatin-344 builds muscle by blocking myostatin/activin (disinhibiting mTOR/Akt), an entirely different mechanism from CJC-1295's GH/IGF-1 elevation. Both converge on protein synthesis and lean mass, so they can be complementary for body-composition goals via independent pathways.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the claimed complementary relationship and shared dimensions. CJC-1295 increases plasma GH and IGF-I through GHRH-R signaling and cAMP-PKA pathways, with IGF-1_signaling and protein_synthesis explicitly tagged. Follistatin-344 blocks myostatin/activin, disinhibiting mTOR/Akt and IGF-1R signaling, also with IGF1_signaling and protein_synthesis tagged. The mechanisms are mechanistically distinct (GH axis elevation vs. TGF-beta antagonism) yet both converge on protein synthesis and lean mass via independent pathways—the definition of complementarity. The explanation accurately reflects the provided mechanism material without contradiction.

    Shares protein synthesis · IGF1 signaling

  • BPC-157Same downstream effect

    Worth caution

    BPC-157 is reported to upregulate growth hormone receptor expression in tendon fibroblasts, sensitizing tissue to GH/IGF-1-driven repair. CJC-1295 raises systemic GH and IGF-1 from a different starting point (GHRH receptor). Together they may converge on the same anabolic/repair output — one increasing the signal (IGF-1), the other increasing receptor availability at the repair site.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism material for BPC-157 lists 'Growth hormone receptor' as a target but provides no evidence it upregulates GH receptor expression in fibroblasts or sensitizes tissue to GH/IGF-1. The explanation asserts this without support from the provided description. While CJC-1295 clearly elevates GH/IGF-1 via GHRH receptor→cAMP/PKA, and BPC-157's pathways include growth factor induction (EGR-1) and tissue repair, the mechanisms do not explicitly establish convergence on GH/IGF-1 signaling as a shared downstream output. The proposed relationship requires an unsupported claim about BPC-157's effect on GH receptor expression to justify the same_downstream classification.
  • AOD-9604Complementary

    May be complementary

    CJC-1295 boosts GH (and downstream IGF-1) through the GHRH receptor, a hormone-mediated path to fat mobilization, while AOD-9604 stimulates lipolysis directly at the adipocyte. The two hit fat loss from different directions and are not redundant with each other.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly activate cAMP-PKA signaling: AOD-9604 via beta3-AR stimulation leading to cAMP elevation and hormone-sensitive lipase activation; CJC-1295 via GHRH-R engagement triggering the cAMP-dependent GH secretory cascade. The proposed relationship correctly identifies that they operate through distinct primary targets (beta3-AR vs GHRH-R) and distinct tissue sites of action (direct adipocyte lipolysis vs pituitary GH axis), making them mechanistically complementary rather than redundant. Both converge on cAMP-PKA as a shared downstream pathway dimension, and the explanation accurately reflects this non-overlapping yet synergistic mechanism architecture described in the provided material.

    Shares cAMP PKA

Safety and side effects

Safety and Tolerability

The Teichman trial reports no serious adverse reactions and describes CJC-1295 as safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg (src-1, src-2, src-5, src-15). A regulatory document reports the most frequently reported adverse events were injection-site reactions (transient pain, swelling, induration, sometimes local urticaria), with no serious adverse reactions in either Phase 1 study; other reported side effects include flu-like symptoms, headaches, irritability, anxiety, nausea, and hives (src-12). A regulatory review lists common side effects including flushing, injection-site erythema, rash, edema, joint and muscle pain, and fatigue (src-3). A comparison article adds mild injection-site reactions (redness, itching), water retention or mild bloating, and rare tingling or numbness in the extremities (src-14). A vendor guide states that Ionescu & Frohman (2006) confirmed GH pulsatility is preserved during continuous CJC-1295 DAC stimulation with no increase in prolactin, cortisol, or ACTH (src-7).

Cautions

A regulatory review cautions that GH may be mitogenic (use with caution in patients prone to or with cancer), may mask symptoms of hypothyroidism (thyroid levels should be tested), and that safety in pediatrics and pregnancy has not been established (src-3). A GH-peptide guide states that GH secretagogues tend to have a more favourable safety and side-effect profile than exogenous HGH — particularly regarding IGF-1 overshoot and glucose dysregulation — because the somatostatin self-regulating mechanism is preserved (src-10, src-14).

The Phase II trial death (attributed differently across sources)

Two regulatory documents report that a 2006 12-week Phase II clinical trial of CJC-1295 DAC in 192 HIV patients with lipodystrophy reported 1 death from myocardial infarction; one notes the attending physician believed it was unrelated to treatment (src-3, src-12). Separately, a peptide guide reports that ConjuChem advanced CJC-1295 DAC through Phase II trials for adult growth hormone deficiency but discontinued clinical development following the death of a participant, reportedly due to a cardiovascular event, and that it never advanced beyond Phase II or gained approval in any jurisdiction (src-4, src-6, src-8).

Regulatory posture and evidence gaps

A peptide guide reports that the FDA's December 4, 2024 Pharmacy Compounding Advisory Committee voted 0 yes, 13 no, 0 abstentions against adding CJC-1295 free base to the 503A bulks list, and that the FDA identified serious adverse events including increased heart rate and a systemic vasodilatory reaction, plus immunogenicity and peptide-impurity risks (src-6). A consumer guide states CJC-1295 is classified as an FDA 503A Category 2 prohibited substance as of April 2026 and is not FDA-approved for any indication (src-13). A comparison article states long-term safety data in healthy adults remain limited, with most research focused on short-term GH/IGF-1 elevations (src-14). A review describes CJC-1295 as an investigational peptide that lacks long-term safety data and systematic validation, with knowledge gaps in optimal dosing, combination-therapy effects, and monitoring biomarkers (src-28), and another notes it is used in sports medicine largely outside regulatory oversight, with favorable animal-model outcomes but scarce rigorous human safety data (src-19). It is prohibited by WADA under category S2 (src-3, src-11, src-13, src-20, src-30).

Reconstitution and handling

Dosing

No dose has been established for this compound. CJC-1295 is not FDA-approved for any indication (src-6, src-8, src-13), and multiple sources note no completed Phase 2 or Phase 3 efficacy trials exist (src-13, src-39); an orthopaedic review states that indications, dosing, frequency, and duration of treatment remain unknown (src-18). The figures below are what sources report — not guidance — and are administered by subcutaneous injection.

  • A regulatory dosing protocol recommends CJC-1295 without DAC at 0.05–0.1 ml QHS (at bedtime), 5 days out of the week, and CJC-1295 with DAC at 600 mcg injected once weekly (src-3).
  • A half-life explainer gives typical CJC-1295 DAC dosing as once weekly 1–2 mg in a single subcutaneous injection, or twice weekly 0.5–1 mg per injection spaced 3–4 days apart, while CJC-1295 without DAC is dosed once daily pre-bed (src-11, src-14).
  • A comparison article states CJC-1295 is often administered 1–2 times per week (src-14).
  • In the Teichman trial, single doses were studied around 30 and 60 μg/kg, with the trial noting good tolerability particularly at 30 or 60 μg/kg (src-1, src-2, src-5, src-15); a pulsatility RCT compared 60 and 90 μg/kg and found no significant difference between responses (src-29).

Pharmacokinetic rationale

A regulatory review reports the once-weekly schedule reflects the DAC half-life of ~6 days (src-3, src-18). A half-life explainer describes CJC-1295 DAC decaying to about 50% of peak by day 6–8 and 25% by day 12–16, versus the non-DAC version reaching 50% of peak at minute 30 and 25% at minute 60 (src-11). A peptide site states pharmacokinetic modeling predicts CJC-1295 DAC reaches steady-state plasma concentrations by the second or third weekly dose, forming an ~70 kDa albumin–CJC-1295 complex (src-4). The Teichman trial reports a cumulative IGF-I effect with multiple doses, IGF-I remaining above baseline up to 28 days (src-1, src-2, src-5, src-15).

Product / preparation notes

A vendor guide lists CJC-1295 with DAC as available in a 2 mg configuration with batch-specific COAs, CAS 863288-34-0, molecular weight ~3,647 Da prior to albumin conjugation, and 30 amino acids (src-7, src-30). A regulatory review lists a molecular weight of 3647.15 and molecular formula C165H269N47O46 (src-3). Note that amino-acid count is reported inconsistently — 29 (the GHRH(1-29) core) versus 30 (counting the DAC/lysine linker) — across sources. The claims provided do not specify a bacteriostatic-water reconstitution volume; concentration after reconstitution depends on the diluent volume added to the labeled 2 mg vial.

Sources

Ordered by evidence quality — the strongest first.

  1. FDA Presentation – CJC-1295(opens in a new tab)
    Tier 1Web · downloads.regulations.gov
  2. Prolonged stimulation of growth hormone (GH) and insulin-like ...(opens in a new tab)
    Tier 1Web · pubmed.ncbi.nlm.nih.gov
  3. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults(opens in a new tab)
    Tier 1Web · researchgate.net
  4. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults(opens in a new tab)
    Tier 1Web · peptidesociety.org
  5. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults - PubMed(opens in a new tab)
    Tier 1Web · pubmed.ncbi.nlm.nih.gov
  6. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  7. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  8. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  9. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  10. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2009
  11. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  12. CJC-1295: Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 2Web · peptideinsight.com · 2026
  13. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  14. Advances in the detection of growth hormone releasing hormone synthetic analogs.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  15. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  16. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2006
  17. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2005
  18. Are Peptides Safe? Evidence, Risks, and Medical Reality - UDS(opens in a new tab)
    Tier 3Web · udshealth.com
  19. CJC-1295 + Ipamorelin | Benefits, Safety & Buying Advice [2026](opens in a new tab)
    Tier 3Web · innerbody.com
  20. CJC-1295 Half-Life Explained: DAC and No-DAC Pharmacokinetics(opens in a new tab)
    Tier 3Web · formblends.com
  21. CJC-1295 vs Ipamorelin: Crucial Medical Steps to Take Now! | Ubie Doctor's Note(opens in a new tab)
    Tier 3Web · ubiehealth.com
  22. Growth Hormone Peptides Guide | CJC-1295, Ipamorelin, Tesamorelin | Meto(opens in a new tab)
    Tier 3Web · meto.co
  23. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  24. CJC-1295 — GHRH(1-29) Analogue (no DAC / DAC variants) — Research Evidence Summary | PeptideStacks(opens in a new tab)
    Tier 3Web · peptidestacks.co.uk · 2026
  25. CJC-1295 — ProPeptideGuide(opens in a new tab)
    Tier 3Web · propeptideguide.com · 2026
  26. CJC-1295 with DAC: Complete Research Guide — Albumin-Binding GHRH Analog, 6–8 Day Half-Life & Human RCT Data (2026) - Your Peptide Brand(opens in a new tab)
    Tier 3Web · yourpeptidebrand.com · 2026
  27. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  28. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  29. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  30. CJC 1295(opens in a new tab)
    Tier 3Web · downloads.regulations.gov · 2006